90
Participants
Start Date
April 27, 2023
Primary Completion Date
September 23, 2024
Study Completion Date
June 30, 2028
Pimicotinib(ABSK021)
capsule
Placebo
capsule
Leiden University Medical Center, Leiden
Roswell Park Comprehensive Cancer Center, Buffalo
Duke University Medical Center, Durham
Fundacion Jimenez Diaz, Madrid
The Ohio State University, Columbus
The Cleveland Clinic Foundation, Cleveland
Henry Ford Health System, Detroit
The University of Texas M.D. Anderson Cancer Center, Houston
Precision NextGen Oncology, Beverly Hills
Fred Hutchinson Cancer Center, Seattle
McGill University Health Center, Montreal
Princess Margaret Cancer Center, Toronto
The First Affiliated Hospital of Bengbu Medical College, Bengbu
Peking University People's Hospital, Beijing
The First Affiliated Hospital of Fujian Medical University, Fuzhou
Guangdong Provincial People's Hospital, Guangzhou
The First Affiliated Hospital of Jinan University, Guangzhou
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
The Affiliated Hospital of Guizhou Medical University, Guiyang
Henan Cancer Hospital, Zhengzhou
The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Hunan Provincial People's Hospital, Changsha
The Second Xiangya Hospital of Central South University, Changsha
Nanjing Drum Tower hospital, Nanjing
Liaoning Cancer Hospital&Institute, Shenyang
Weifang People's Hospital, Weifang
Shanghai General Hospital, Shanghai
The Second Hospital of Shanxi Medical University, Taiyuan
Xi'an Honghui Hospital, Xi’an
West China Hospital Sichuan University, Chengdu
The First Affiliated Hospital of Xinjiang Medical University, Ürümqi
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Beijing Jishuitan Hospital, Beijing
IRCCS Istituto Ortopedico Rizzoli, Bologna
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Ospedale di Prato, Prato
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw
Hospital Universitari Vall d'Hebron, Barcelona
Lead Sponsor
Abbisko Therapeutics Co, Ltd
INDUSTRY